Novel therapies for the treatment of prostate cancer: Current clinical trials and development strategies

Surgical Oncology

Volumn 11, Issue 1-2, 2002, Pages 13-23

  Morris, Michael J ^a,b   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antineoplastic therapy; Biologic therapy; Gene therapy; Immunotherapy; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; ATRASENTAN; CALCITRIOL; CETUXIMAB; DOCETAXEL; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRAMUSTINE; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GANCICLOVIR; GELDANAMYCIN; HERBIMYCIN; KEYHOLE LIMPET HEMOCYANIN; MUCIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; PROTEIN P53; QS 21; RETINOID X RECEPTOR; ROSIGLITAZONE; THALIDOMIDE; THYMIDINE KINASE; TRASTUZUMAB; TROGLITAZONE; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D RECEPTOR; VORINOSTAT;

ADJUVANT THERAPY; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; DRUG TOLERANCE; FEVER; GENE THERAPY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; MALAISE; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VITAMIN D RESPONSIVE ELEMENT;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; APOPTOSIS; CLINICAL TRIALS; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THALIDOMIDE;

EID: 0036273771     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(02)00006-3     Document Type: Article

References (111)

1. Clinical states in prostate cancer: Towards a dynamic model of disease progression
2. HER-2 profiling and targeting prostate carcinoma: A phase II trial of trastuzumab alone and with paclitaxel
3. Her-2-neu expression and progression toward androgen independence in human prostate cancer
4. Evaluation of a nomogram for predicting pathological stage of men with clinically localized prostate cancer
5. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
6. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
7. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
8. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
9. Results of a phase II study using estramustine phosphate and vinblastine combination and high dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer
10. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results
11. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
12. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
13. P53 protein accumulation and gene mutation in the progression of human prostate carcinoma
14. P53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential
15. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
16. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector
17. Intraprostatic Ad-p53 gene therapy induces apoptosis in locally advanced adenocarcinoma of the prostate
18. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control
19. Targeted therapy for prostate cancer: The MSKCC approach
20. Heterogeneity of mucin gene expression in normal and neoplastic tissues
21. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin
22. Structure and biology of a carcinoma-associated mucin, MUC1
23. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma
24. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines
25. Targeted therapy in prostate cancer (PC): Vaccination with a glycoprotein, muc-1-KLH-QS-21 peptide conjugate
26. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
27. Evaluation of Tn(c)-KLH and Tn(c)-PAM vaccine conjugates plus the immunologic adjuvant, QS 21, in biochemically relapsed prostate cancer: Candidate antigen for multivalent phase III vaccine trial
28. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
29. Immunotherapy with prostatic acid phosphatase-loaded dendritic cells (PROVENGE) in prostate cancer patients with serologic progression after definitive local therapy
30. Angiogenesis in cancer, vascular, rheumatoid, and other disease
31. Thalidomide is an inhibitor of angiogenesis
32. Immediate hormonal therapy vs. observation for node positive prostate cancer following radical prostatectomy: A randomized phase III Eastern Cooperative Oncology Group/Inter Group Trial
33. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of radiation therapy oncology group protocol 85-31
34. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
35. Identification of endothelin-a in the pathophysiology of metastatic adenocarcinoma of the prostate
36. The endothelin - A receptor antagonist Atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer
37. The endothelin - A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: A multinational, randomized, double-blind, placebo-controlled trial
38. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma
39. Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan
40. Prospective evaluation of hydrocortisone and suramin
41. Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer
42. PSA velocity for the diagnosis of early prostate cancer. A new concept
43. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: An analysis of cancer and leukemia group B study of 9181 megestrol acetate
44. A prognostic score for hormone-refractory prostate cancer: Analysis of two Cancer and Leukemia Group B studies
45. Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials
46. Clinical trials in relapsed prostate cancer: Defining the target
47. HER2 expression in androgen-independent prostate cancer
48. Expression of bc1-2 and the progression of human and rodent prostatic cancers
49. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
50. Vitamin D receptor expression, 23-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines
51. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25-dihydroxyvitamin D3
52. Feldman D: Vitamin D and prostate cancer: 1,25 dihydroxy vitamin D3 receptors and actions in human prostate cancer cell lines
53. Antiproliferative effects of, 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells
54. Vitamin D and prostate cancer: 1,25 dihydroxy vitamin D3 receptors and actions in human prostate cancer cell lines
55. Vitamin D in the prevention and treatment of prostate cancer
56. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
57. 1 alpha, 25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms
58. Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues
59. A phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
60. Treatment of early recurrent prostate cancer with 1,25-dyhidroxyvitamin D3 (calcitriol)
61. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
62. Preliminary results: Phase II trial of troglitazone for androgen-dependent (AD) and androgen-independent (AI) prostate cancer
63. Hybrid polar compounds suppress the growth of the CWR22 human prostate cancer xenograft
64. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
65. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
66. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: Biologic activity without toxicity
67. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
68. A phase II trial of Herceptin alone and with paclitaxel for the treatment of prostate cancer
69. HER-2/neu (p185neu) protein expression in the natural and treated history of prostate cancer
70. The role of heat shock proteins in regulating the function, folding and trafficking of the glucocorticoid receptor
71. The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors
72. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase
73. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway
74. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
75. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family
76. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest
77. Herbimycin A induces the 20S proteosome- and ubiquitin-dependent degradation of receptor tyrosine kinases
78. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (Pts) with advanced solid malignancies
79. Regulation of prostatic growth and function by peptide growth factors
80. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines
81. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
82. Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): Results of a phase Ib/IIa study
83. The proteosome: A macromolecular assembly designed to confine proteolysis to a nanocompartment
84. The ubiquitin system for protein degradation
85. The ubiquitin-proteasome pathway: On protein death and cell life
86. How proteolysis drives the cell cycle
87. An essential role for NF-kB in preventing TNF-α-induced cell death
88. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers
89. Proteasome inhibitors: A novel class of potent and effective antitumor agents
90. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
91. Dose dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (PTS) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341
92. The apoptosis-suppressing oncoprotein, bcl-2 is expressed in germinal layers of human prostate gland in various stages of prostatic oncogenesis
93. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers
94. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
95. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy
96. Effects of Ca++ mobilization on expression of androgen-regulated genes: Interference with androgen receptor-mediated transactivation by AP-1 proteins
97. A phase I trial of BCL2 antisense drug G3139 (Genta, Inc.) delivered by continuous intravenous infusion alone and in combination with weekly paclitaxel
98. A phase I/IIa dose-escalating trial of BCL-2 antisense (G3139) treatment by 14-day continuous intravenous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies
99. A phase I trial of BCL2 antisense drug G3139 (Genta, Inc.) delivered by continuous intravenous infusion alone and in combination with weekly paclitaxel
100. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (Genasense) and docetaxel (D) in hormone refractory prostate cancer
101. Angiogenesis in cancer, vascular, rheumatoid, and other disease
102. Tumor angiogenesis: Therapeutic implications
103. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells
104. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines
105. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
106. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo
107. Urokinase and gelatinases in the proteolytic cascade in human prostate cancer invasion: Implications in cancer prevention and intervention
108. Serum metalloproteinases and their inhibitors: Markers for malignant potential
109. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC)
110. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
111. Phase I clinical trial targeting a monoclonal antibody (mAb) the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer